Table 1 Patient characteristics of the 102 patients including 51 breast cancer cases and 51 matched controls.
Characteristics | Cancer cases (nā=ā51) N (%) | Controls (nā=ā51) N (%) | |
|---|---|---|---|
Age (years): meanāĀ±āSD (range) | 47.6āĀ±ā7.4 (34ā60) | 47.1āĀ±ā7.3 (31ā60) | |
Menopausal status | |||
Ā Premenopausal | 28 (55%) | 30 (59%) | |
Ā Postmenopausal | 23 (45%) | 21 (41%) | |
MRI performed outside the second week of the menstrual cycle for premenopausal women | 15 (29%) | 15 (29%) | |
Diagnostic BI-RADS findings of single-side breast on mammography and/or ultrasound | |||
Ā Breast with lesion (cancer/benign) | BI-RADS 4 | 11 (22%) | 47 (92%) |
BI-RADS 5 | 40 (78%) | 4 (8%) | |
Ā Contralateral breast | BI-RADS 1 | 27 (53%) | 21 (41%) |
BI-RADS 2 | 19 (37%) | 25 (49%) | |
BI-RADS 3 | 1 (2%) | 1 (2%) | |
BI-RADS 4 | 4 (8%) | 4 (8%) | |
History of prior breast cancer | 0 (0%) | 0 (0%) | |
Family history of breast cancer | 26 (51%) | 31 (61%) | |
Family history of ovarian cancer | 3 (6%) | 0 (0%) | |
Known pathogenic BRCA1/2 mutation | 2 (4%) | 0 (0%) | |
Prior biopsy (>1 year prior to the studied biopsy) | |||
Ā Atypia | 1 (2%) | 0 (0%) | |
Ā Benign abnormality | 9 (18%) | 6 (12%) | |
Ā Exogenous hormone use | |||
Ā Hormone replacement therapy | 7 (14%) | 5 (10%) | |
Ā Birth control pills | 33 (65%) | 34 (67%) | |
Ā Tamoxifen | 1 (2%) | 0 (0%) | |
Ā None | 5 (10%) | 12 (24%) | |
Cancer type | |||
Ā Ductal carcinoma in situ (DCIS) | 2 (4%) | ā | |
Ā Invasive ductal carcinoma (IDC) | 26 (51%) | ā | |
Ā Invasive lobular carcinoma (ILC) | 4 (8%) | ā | |
Ā Mixed of IDC and DCIS | 18 (35%) | ā | |
Ā Invasive mixed ductal-lobular carcinoma | 1 (2%) | ā | |
Tumor size | |||
Ā ā¤2ācm | 18 (35%) | ā | |
Ā 2ā5ācm | 31 (61%) | ā | |
Ā >5ācm | 2 (4%) | ā | |
